LBRX
LB Pharmaceuticals Inc
44.71
-0.23 (-0.51%)
52w low 14.40
50.16 high
84.8% of range
Financial Analysis
| (USD) | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 4.86M | 5.25M | 13.87M | 22.10M | 53.91M | |
| R&D | 2.42M | 2.42M | 8.48M | 14.64M | 44.15M | |
| SG&A | 2.44M | 2.83M | 5.39M | 7.46M | 9.77M | |
| Operating Income | -4.86M | -5.25M | -13.87M | -22.10M | -53.91M | |
| EBITDA | -4.78M | -5.17M | -13.79M | -22.02M | -53.82M | |
| Pretax Income | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M | |
| Income Tax | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | |
| Net Income | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M | |
| EPS Diluted | -0.22 | -0.61 | -0.45 | -0.67 | -1.71 | |
| Diluted Shares | 22.44M | 5.81M | 25.41M | 28.24M | 30.14M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--